Immunogenicity and safety of a respiratory syncytial virus fusion protein (RSV F) nanoparticle vaccine in older adults

Immunity and Ageing

Volumn 14, Issue 1, 2017, Pages

  Fries, Louis ^a   Shinde, Vivek ^a   Stoddard, Jeffrey J ^a   Thomas, D Nigel ^a   Kpamegan, Eloi ^a   Lu, Hanxin ^a   Smith, Gale ^a   Hickman, Somia P ^a   Piedra, Pedro ^b   Glenn, Gregory M ^a  

^a NOVAVAX INC   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Anti F IgG; Avidity; F or fusion protein; Microneutralization; Nanoparticle vaccine; Palivizumab competitive antibody (PCA); Recombinant; Respiratory syncytial virus (RSV)

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; INFLUENZA VACCINE; RECOMBINANT PROTEIN; RESPIRATORY SYNCYTIAL VIRUS FUSION PROTEIN VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE;

ADULT; AGED; AGING; ANTIBODY BLOOD LEVEL; ANTIGEN BINDING; ARTHRALGIA; ARTICLE; BACKACHE; CONTROLLED STUDY; DRUG FORMULATION; DRUG SAFETY; FATIGUE; FEMALE; HEADACHE; HEMAGGLUTINATION INHIBITION; HUMAN; HUMAN EXPERIMENT; HUMAN RESPIRATORY SYNCYTIAL VIRUS; HYPERTENSION; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; MYALGIA; NORMAL HUMAN; OROPHARYNX PAIN; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY SYNCYTIAL VIRUS INFECTION; SINGLE DRUG DOSE; UPPER RESPIRATORY TRACT INFECTION;

EID: 85018485945     PISSN: None     EISSN: 17424933     Source Type: Journal    
DOI: 10.1186/s12979-017-0090-7     Document Type: Article

References (17)

1. Branche AR, Falsey AR. Respiratory syncytial virus infection in older adults: an under-recognized problem. Drugs Aging. 2015;32:261-9. doi: 10.1007/s40266-015-0258-9.
2. Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med. 2005;352:1749-59. doi: 10.1056/NEJMoa043951.
3. Zhou H, Thompson WW, Viboud CG, Ringholz CM, Cheng PY, Steiner C, et al. Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993-2008. Clin Infect Dis. 2012;54:1427-36. doi: 10.1093/cid/cis211.
4. Fleming DM, Taylor RJ, Lustig RL, Schuck-Paim C, Haguinet F, Webb DJ, et al. Modelling estimates of the burden of respiratory syncytial virus infection in adults and the elderly in the United Kingdom. BMC Infect Dis. 2015;15:443. doi: 10.1186/s12879-015-1218-z.
5. Matias G, Taylor R, Haguinet F, Schuck-Paim C, Lustig R, Shinde V. Estimates of mortality attributable to influenza and RSV in the United States during 1997-2009 by influenza type or subtype, age, cause of death, and risk status. Influenza Other Respir Viruses. 2014;8:507-15. doi: 10.1111/irv.12258.
6. Walsh EE, Falsey AR. Respiratory syncytial virus infection in adult populations. Infect Disord Drug Targets. 2012;12:98-102.
7. Raghunandan R, Lu H, Zhou B, Xabier MG, Massare MJ, Flyer DC, et al. An insect cell derived respiratory syncytial virus (RSV) F nanoparticle vaccine induces antigenic site II antibodies and protects against RSV challenge in cotton rats by active and passive immunization. Vaccine. 2014;32:6485-92. doi: 10.1016/j.vaccine.2014.09.030.
8. Smith G, Raghunandan R, Wu Y, Liu Y, Massare M, Nathan M, et al. Respiratory syncytial virus fusion glycoprotein expressed in insect cells form protein nanoparticles that induce protective immunity in cotton rats. PLoS One. 2012;7:e50852. doi: 10.1371/journal.pone.0050852.
9. Glenn GM, Smith G, Fries L, Raghunandan R, Lu H, Zhou B, et al. Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine. Vaccine. 2013;31:524-32. doi: 10.1016/j.vaccine.2012.11.009.
10. Glenn GM, Fries LF, Thomas DN, Smith G, Kpamegan E, Lu H, et al. A randomized, blinded, controlled, dose-ranging study of a respiratory syncytial virus recombinant fusion (F) nanoparticle vaccine in healthy women of childbearing age. J Infect Dis. 2016;213:411-22. doi: 10.1093/infdis/jiv406.
11. Kpamegan E, Zheng L. Concordance Between Laboratories Testing Clinical Samples and Its Impact on Vaccine Booster Thresholds. J Stat Sci Appl. 2014;2:55.
12. Poulsen TR, Jensen A, Haurum JS, Andersen PS. Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans. J Immunol. 2011;187:4229-35. doi: 10.4049/jimmunol.1000928.
13. Falsey AR, Walsh EE, Capellan J, Gravenstein S, Zambon M, Yau E, et al. Comparison of the safety and immunogenicity of 2 respiratory syncytial virus (RSV) vaccines--nonadjuvanted vaccine or vaccine adjuvanted with alum--given concomitantly with influenza vaccine to high-risk elderly individuals. J Infect Dis. 2008;198:1317-26. doi: 10.1086/592168.
14. Piedra PA, Jewell AM, Cron SG, Atmar RL, Glezen WP. Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies. Vaccine. 2003;21:3479-82.
15. Walsh EE, Falsey AR. Humoral and mucosal immunity in protection from natural respiratory syncytial virus infection in adults. J Infect Dis. 2004;190:373-8. doi: 10.1086/421524.
16. Suara RO, Piedra PA, Glezen WP, Adegbola RA, Weber M, Mulholland EK, et al. Prevalence of neutralizing antibody to respiratory syncytial virus in sera from mothers and newborns residing in The Gambia and in the United States. Clin Diagn Lab Immunol. 1996;3:477-9.
17. Falsey AR, Singh HK, Walsh EE. Serum antibody decay in adults following natural respiratory syncytial virus infection. J Med Virol. 2006;78:1493-7. doi: 10.1002/jmv.20724.